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doi:10.1016/j.hkpj.2011.06.003Abstract Glucosamine administration is being speculated to alter glucose metabolism and
few studies had investigated the effects to confirm this speculation. It is not known if glucos-
amine sulphate administration through the process of iontophoresis will contradictorily raise
the plasma glucose being a sugar. Fifty-two participants with Knee osteoarthritis were
randomly assigned to 3 groups: Group 1 participants received exercise therapy followed by
administration of 300 mg (an equivalent of 3 mL) of glucosamine sulphate through iontopho-
resis. Group 2 also received an equivalent of 3 mL glucosamine sulphate iontophoresis without
exercise whereas Group 3 received exercise therapy only. Glucometer (One Touch-Ultra easy
model) was used to monitor the pre and post fasting plasma glucose. Descriptive and inferen-
tial statistics (analysis of variance) were used. The result of analysis of variance showed that
there was no significant difference in the final fasting blood sugar (FBS) of the 3 groups. Within
session assessment for Group 1 showed that there was also no significant difference in the FBS
at different phases of interventions. However, for Group 2, there was significant reduction in
FBS immediately after iontophoresis (p < 0.05). Similarly, for Group 3, the FBS was significantly
lowered immediately after exercise (p < 0.03). This study concluded that Glucosamine
sulphate iontophoresis did not raise plasma concentration of glucose.
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In mammals, the blood glucose level is maintained at
a reference range between 3.6mM and 5.8mM (mmol/L)
and it is regulated by metabolic homeostasis [1]. Exercise is
considered a cornerstone in the prevention and correction
of excess glucose [2]. Aerobic endurance exercise has been
advocated as the most suitable exercise mode to prevent
and treat excess glucose [3]. Exercise had been docu-
mented to be medicinal [4]. But controversy still trails its
effect and efficiency when used in conjunction with other
modalities or drugs [5].
There is evidence that osteoarthritis is an inevitable part
of aging and it is usually associated with diabetes. Obesity,
work-related injuries, and injuries due to sports are also
part of the causes of osteoarthritis [6]. The incidence of
arthritis is rampant among elite performance athletes
compared with nonathletes [7]. Glucosamine (a sugar) is
one of the recent nutritional supplements that are being
considered as possible means of relieving pain arising form
arthritis. Most athletes subscribe to dietary intake of
glucosamine supplement to combat inflammation, rehabil-
itate cartilage, and promote healthier joints [7]. Athletes
have discovered the benefits of glucosamine liquid
compound in training and daily life [7].
The human body depends on glucosamine, an amino
sugar, for the synthesis of connective tissue and cartilage.
Glucosamine is used as the starting material for tendons
and ligaments, mucous membranes in the digestive and
respiratory tracts, and synovial fluid in the joints. It also
supports healthy mucous secretion of the digestive, respi-
ratory, and urinary tracts [8]. There is evidence that
glucosamine also helps to improve the structure of joints
[9]. Braham et al, [10] suggested that glucosamine
supplementation could provide some degree of pain relief
and improve function in person who experiences regular
knee pain, as a result of cartilage injury or osteoarthritis.
The study of the penetration of drugs through the skin
has become increasingly important in recent years. The
aims of such enhanced and controlled delivery are to
maximize the bioavailability of the drug, to optimize the
therapeutic efficacy, and to minimize side effects. There
are various means of delivering pharmaceutical-drugs
medication transcutaneously [11]. The defect usually
associated with these methods is side effects in the
gastrointestinal tract. To avoid side effects, complemen-
tary technique such as iontophoresis is being advocated.
Many topical compositions such as glucosamine sulphate
creams have been developed to by-pass the gastrointestinal
tract and therefore mitigate the adverse effects associated
with oral administration. Such topical compositions also
have the additional advantage of acting much faster in
relieving pain and inflammation. However, a challenge
remains in optimizing and enhancing the therapeutic
effects of these topical compositions [12]. Chondroitin
sulphate and glucosamine are the best studied and there-
fore the preferred chondroprotective agents for use in the
present invention [12]. A typical dosage of glucosamine salt
ranges between 340 mg and 1,500 mg per day, although,
a substantial part remains in the liver leaving very little
freed glucosamine to reach the cartillge (reducedbioavailability), [13,14]. A dose of 500 mg, an equivalent of
5 mL, of glucosamine liquid was observed to be detectable
in the plasma [13]. However, Lee et al [14] used what they
considered to be a high dose of glucosamine sulphate cream
[1000 mg] and they observed a detectable glucosamine
within 30 minutes of application. Onigbinde et al [15,16]
found that 3 mL of glucosamine sulphate cream, an
equivalent of 300 mg, had significant effect in reducing pain
among participants with knee osteoathritis when adminis-
tered through iontophoress. Lee et al [14] reported that
transdermal delivery of glucosamine is much more effective
than oral delivery to the synovial fluid if applied close to
the joints.
Only very few studies had investigated the effect of
glucosamine on plasma sugar level. Glucosamine is pres-
ently in wide use because of its purported beneficial effects
in patients with osteoarthritis. Alterations in glucose
control have not been documented in trials of short dura-
tion exercises conducted in healthy or diabetic participants
[17]. It is important to consider glucosamine effect on
glucose metabolism, especially when being used in
conjunction with exercise therapy. Although exercise
depletes glucose, the administration of sugar may increase
the glucose concentration.
Theoretically, glucosamine may altar glucose metabo-
lism. Insulin resistance has been noted following intrave-
nous administration of glucosamine in animal studies;
however, these findings have not been confirmed in
humans. Contradictory reports have continued to trail the
effects of glucosamine on blood glucose level [18e20].
Few studies had investigated the effects of glucosamine
sulphate on plasma glucose and the modes of administra-
tion were through oral or intravenous routes. Furthermore,
a few number of participants (14e16 participants) took part
in the studies [21,22]. Issues are being raised about the
possibility of glucosamine interfering with blood glucose
control. A recent review of the literature on this topic
concluded that although alterations in glucose metabolism
that have been noted in animals gave high glucosamine,
similar effects have not been consistently documented in
humans following usual oral doses [23].
It appears that there are limited investigations on the
effect of glucosamine sulphate iontophoresis on acute
exercise-stimulated glucose. Although exercise depletes
plasma glucose, it is not known that the glucosamine
sulphate administration through iontophoresis will contra-
dictorily raise the plasma glucose, being a sugar. It is sug-
gested that patients with diabetes should monitor their
blood glucose levels regularly, if glucosamine is initiated,
the dose is increased or the product being taken is changed
[23,24].
The primary objective of this study was to determine
whether plasma glucose concentration of participants with
knee osteoarthritis who received combination of glucos-
amine sulphate and exercise would differ from that of
subjects who received glucosamine sulphate or exercise
alone. It was hypothesized that there would be no signifi-
cant difference in the plasma glucose concentration of
participants who received combination of glucosamine
sulphate and exercise and those who received glucosamine
sulphate or exercise alone.
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Population of the study
The participants were patients with knee-joint osteoar-
thritis receiving treatment at the physiotherapy depart-
ment of Obafemi Awolowo University Teaching Hospital
Complex, Ile-Ife, Osun State, Nigeria. Sixty participants
who met inclusive criteria were recruited from a population
of 87 participants with knee osteoarthritis. The sixty
participants were randomly assigned into 3 groups with 20
participants in each group, but only 52 participants
completed the study. This was as a result of long waiting
period for interventions to be completed and those that
dropped out could not wait to complete the procedure. All
the participants were nondiabetic, nonathlete, and were
without nutritional disorders. Furthermore, participants
who presented with malnutrition, fever, tumors, cardio-
vascular disorders, pregnancy, skin diseases, knee osteo-
arthritis greater than 3 months duration of onset, and those
with cardiac pacemaker or any metallic implant were
excluded from the study.
Sample and sampling technique
The sample consisted of purposively selected patients with
knee-joint osteoarthritis who consented to participate in
the study. They were randomly assigned to 3 groups. The
random assignment was in order of arrival, that is, the first
participant was selected into Group 1, second participant
to Group 2, and 3rd participant to Group 3; the 4th to
Group 1 again and this continued in that order.
Research design
This study was a quasi-experimental design. Blood samples
were obtained before (pretest) and immediately after each
intervention (posttest).
Instrumentation
A Bathroom Weighing Scale (Hanson, Germany), modified
was used to measure the weights of each participants and it
was graded in kilogram whereas a Stadiometer was used to
measure the height of each participant. An Electrical
Stimulator (Model: Endomed 582, 10060; Enraf Nonius) was
used as the source of interrupted galvanic current for the
purpose of iontophoresis. The accessories are stimulation
tray, which consisted of a bottle containing 70% alcohol to
clean the surface of the skin where electrodes was placed;
cotton wool; a bowl of water; and lint, which was used to
cover the electrodes of the stimulator during iontophoresis.
Spatula was used to quantify the amount of Urah Trans-
dermal glucosamine sulphate cream (glucosamine sulphate
8% w/w), 300 mg, an equivalent of 3 mL [5]. Glucometer
(One Touch-Utra easy model; LIFESCAN-Johnson & Johnson
Company, 021-195) was used to determine the blood sugar
level (Fasting plasma glucose in mg/dL). Other accessories
are lancet needle, injector, and test strips whereas Cycle
ergometer (Bodyguard model) was used as the exerciser.Before the study, a pilot study was conducted to
determine the reliability of the glucometer. Ten partici-
pants were recruited for the reliability study. On Day 1,
their fasting blood sugar (FBS) was obtained and they were
subjected to repeated tests on Day 2 after 1 week. The
reliability co-efficient was computed and it was found to be
0.93 (p > 0.05). This showed that the glucometer is reliable
for measuring FBS. Furthermore, the glucometer was found
to be highly sensitive and specific and its result correlates
significantly well with the laboratory method [25].
Procedure for data collection
Approval was granted by the Ethic and Research Board of
Obafemi Awolowo University Teaching Hospital Complex,
Ile-ife, Osun State Nigeria. The participants were randomly
selected into 3 groups: Group 1 comprises 20 participants
who received exercise therapy followed by glucosamine
sulphate iontophoresis. Group 2 comprises 15 participants
who received glucosamine sulphate iontophoresis without
exercise whereas Group 3 comprises 17 participants who
received exercise therapy alone.
The first group exercised on cycle ergometer for
15 minutes after which they received 300 mg of glucos-
amine sulphate cream (an equivalent of 3 mL) by means of
Electrical stimulator. Glucosamine cream was placed on the
active electrodes (glucosamine being the active ingredient
is positively charged), [26]. The active electrode was
placed on the medial side of the knee (after the skin
surface was cleaned with 70% alcohol to minimize the risk
of burns [27]). The inactive electrode was placed on the
lateral side of the knee joint. With both electrodes held in
place by an adhesive strap, the stimulator was switched on,
turned to direct current mode, and the intensity was
gradually increased and maintained at the patient’s pain
threshold for 15 minutes [28].
For Group 1, a drop of blood sample was obtained
through the use of a sterile lancet tip on the thumb of each
participant before ergometer exercise (pretest), immedi-
ately after exercise, immediately after iontophoresis (post
test), and 30 minutes post iontophoresis [21,29]. The
recovery glucose was monitored at 30 minutes post ionto-
phoresis. Most participants had detectable glucosamine at
30e45 minutes, even as early as 15 minutes [18].
The second group received the same quantity of
glucosamine sulphate cream and the same process of
iontophoresis as in Group 1 but without any form of exer-
cise. The 3rd group, which served as control, received only
cycle ergometry for 15 minute. The FBS value was also
obtained for the participants as in Group 1 using Gluc-
ometer . All the subjects fasted overnight (with last meal
not exceeding 10 pm of the previous day) and all morning
drugs were withheld on measurement days until after the
experimental procedure. At each testing, fresh needle was
used for each of the participant at every prick to avoid
cross infection.
Data analysis
Both the descriptive and inferential statisticswere used. The
descriptive statistic was used to describe the data obtained.
Table 2 Result of comparison of FBS across the 3 groups
Variables Groups Mean FBS SD F p
Initial 1 126.10 13.23
2 129.00 9.58
3 129.65 9.91 0.53 0.59
Final 1 119.20 12.94
2 115.00 10.10
3 121.12 9.26 1.27 0.29
FBS 30 min 1 119.50 12.67
2 111.00 11.64
3 118.47 8.52 2.82 0.07
FBS Z fasting blood sugar; SD Z standard deviation.
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for age, body mass index, weight, and plasma glucose level.
An inferential statistic- analysis of variance was used to
determine the significant differences in blood sugar levels of
the 3 groups. Post hoc analyses were done to show the mean
differences of the variables where significant differences
were observed. The level of significance was set as 0.05.
Results
The result of the anthropometric parameters was pre-
sented in Table 1. The result showed 3.5% drop in FBS
immediately after exercise and a further drop by 2.05%
after glucosamine sulphate iontophoresis whereas the
recovery of FBS after 30 minutes of resting increased by
0.25%. The total decrease in FBS was 5.20% between initial
FBS and final FBS (after 30 minutes resting), (Table 2).
Similarly, for Group 2 participants, the FBS after ionto-
phoresis dropped by 10.85% whereas the FBS further drop-
ped by 3.48% after 30 minutes resting. The total drop in FBS
from initial value to final FBS after 30 minutes was 13.95%
(Table 3). For Group 3 participants there was 6.58%
decrease in FBS. The recovery FBS after 30 minutes further
dropped by 2.19% showing a total drop in FBS from initial
value to final FBS after 30 minutes by 8.62% (Table 3).
The result of the analysis of variance showed that there
was no significant difference in the initial FBS of the 3
groups (F Z 0.526, p > 0.59). Similarly, there was no
significant difference in the final FBS of the 3 groups
(FZ 1.27, p > 0.29). Furthermore, there was no significant
difference in the recovery of final blood sugar of the 3
groups after 30 minutes rest (FZ 2.82, p > 0.07), (Table 2).
Comparison of FBS within the groups
There was also no significant difference in the FBS of Group
1 participants when the initial FBS was compared with theTable 1 Anthropometric parameters of participants in the
3 groups
Groups N Mean values SD
Age
1 20 63.35 10.17
2 15 70.00 4.86
3 17 52.29 16.60
Height (m)
1 20 1.62 0.09
2 15 1.57 0.04
3 17 1.67 0.06
Weight (kg)
1 20 73.15 22.45
2 15 72.00 7.32
3 17 74.21 7.00
BMI (kg m2)
1 20 29.22 4.77
2 15 29.28 2.51
3 17 26.90 4.06
BMIZ body mass index; NZ number; SDZ standard deviation.FBS immediately after exercise on cycle ergometer,
immediately after glucosamine sulphate iontophoresis, and
immediately after 30 minutes of rest (F Z 1.21, p > 0.31).
However, there was significant difference in the FBS of
Group 2 participants who had only glucosamine sulphate
iontophoresis when the initial FBS was compared with the
FBS immediately after iontophoresis and immediately after
30 minutes of rest (F Z 8.90, p < 0.001). The result of the
Post hoc analysis (Scheffe) showed that there was signifi-
cant reduction in FBS after iontophoresis, (p < 0.05) and
after 30 minutes of rest (p < 0.001), (Table 3).
Similarly, among Group 3 participants who exercised on
cycle ergometer alone, there was significant difference
(FZ 6.78, p< 0.03) when the initial FBS was compared with
the FBS immediately after exercise and after 30 minutes
rest. The result of the Post hoc analysis showed that the FBS
was significantly lower immediately after exercise (p< 0.03)
and after 30 minutes rest (p < 0.004), (Table 4).
Discussion
Drug education, actions, and interactions are areas where
attention should be focused, especially in areas whereTable 3 Comparison of the FBS within each group
Mean FBS SD %
decrease
F p
Group 1
Initial 126.10 13.23
After exercise 121.70 13.68 3.50
After iontophoresis 119.20 12.94 2.05
After 30 min 119.50 12.67 0.25* 1.21 0.31
Group 2
Initial 129.58 9.58
After iontophoresis 115.00 10.10 10.85
After 30 min 111.00 11.64 3.48 8.90 0.001**
Group 3
Initial 129.65 9.91
After exercise 121.18 9.26 8.62
After 30 min 118.47 8.52 2.19 6.78 0.03*
*Significant at p < 0.05; **Significant at p < 0.001.
FBS Z fasting blood sugar; SD Z standard deviation.
Table 4 Result of post hoc analysis comparing the FBS within Groups 2 and 3 participants
Groups Mean difference p
Group 2 initial FBS FBS after iontophoresis 8.40 0.173
FBS after 30 min 18.00 0.001*
Group 3 initial FBS FBS after exercise 8.53 0.03**
FBS after 30 min 11.18 0.004***
*Significant at p < 0.001; **Significant at p < 0.05; ***Significant at p < 0.01.
FBS Z fasting blood sugar.
83there are overlaps in action of drugs and exercise therapy
such as in glucose control. Medical evaluation is a premier
step in exercise training prescription [30]. There are
a variety of conditions that need to be considered in
understanding hypoglycemia during exercise, including the
type and duration of exercise and glucose concentrations
before starting exercise. Human blood glucose levels nor-
mally remain within a remarkably narrow range. In most
humans this varies from 80 mg/dL to 110 mg/dL (4 mmol/L
to 6 mmol/L) except shortly after eating, when the blood
glucose level rises temporarily up to may be 140 mg/dL
(7e8 mmol/L) or a bit more in nondiabetics [31]. The
homeostatic mechanism, which regulates the blood value
of glucose in a remarkably narrow range, comprises several
interacting systems, of which hormone regulation is the
most important. Glucosamine has been observed to cause
insulin resistance by inhibiting insulin-stimulated glucose
transport in the hexosamine pathway [32].
This study used a single dose because Biggee et al [18]
used a single dose of glucosamine as it disappears from
human plasma by 5 hours and also because of a study with
dogs that found no significant differences between single
dose and multiple dose pharmacokinetics [33]. The result of
this study showed that there was no significant difference
in the final FBS of the participants who had combination of
both exercise therapy and iontophoresis, those who had
only glucosamine sulphate iontophoresis, and those who
had exercise therapy alone. This study tended to support
that of Stumpf and Lin [27] who also reported that glucos-
amine did not affect glucose tolerance or insulin resistance
in nondiabetic subjects. Similarly, Joseph et al [22]
observed that despite long duration treatment with
glucosamine sulphate for 4 weeks, there was no change in
fasting plasma glucose. Stumpf and Lin [17] also reported
that small and short-term studies suggested that glucos-
amine may be used in selected patients without affecting
glucose control. This present finding still lent support to
that of Biggee et al [18] who also found an insignificant
mean incremental elevation in plasma glucose among
osteoarthtritic subjects, although, they suggested that
glucosamine ingestion may affect glucose levels and
consequent glucose uptake in patients who have untreated
diabetes or glucose intolerance.
Iontophoresis has been demonstrated to “drive” some
drugs to a tissue depth of 5e20 mm even up to 1.7 cm [34].
Despite the amount of glucosamine in blood after oral
administration, it was only a quarter of the amount that is
available after intravenous and intramuscular administra-
tions [35]. The actual concentration of glucose in blood is
very low, even in the hyperglycemic [1]. Althoughiontophoresis delivers less than a local injection, it provides
much higher local concentrations than oral administration
[36]. Transdermal administration means that the drug may
be introduced into the systemic circulation without initially
entering the portal circulation where it may be metabo-
lized into a pharmacologically inactive form (first pass
effect) [37]. During iontophoresis, drug is delivered directly
into the bloodstream without delays due to absorption
through the gastrointestinal tract.
There were also no significant changes in the FBS within
Group 1 participants at different phases of intervention,
when the initial FBS was compared with the FBS immedi-
ately after exercise on cycle ergometer and immediately
after glucosamine sulphate iontophoresis. However, there
was significant reduction in the FBS of Group 2 participants
immediately after glucosamine sulphate iontophoresis and
after 30 minutes of rest with significant reduction of 10.85%
and 3.48%, respectively in the plasma glucose. This may be
attributed to a process of reverse iontophoresis. In reverse
iontophoresis the negative charge of the skin at buffered
pH causes it to be permselective to cations causing solvent
flow towards the anode. This flow is the dominant force
allowing movement of neutral molecules, including
glucose, across the skin [38]. The reduction in glucose level
was almost comparable with that observed using exercise
to deplete glucose [24].
Among Group 3 participants, the FBS was significantly
lowered immediately after exercise and after 30 minutes
rest with 8.62% and 2.19% reduction respectively. The
reduction found in this study was low when compared with
that of previous studies. This may be attributed to knee
joint impairment that arose from the pathological effects
of knee osteoarthtritis. The participants were unable to
pedal with high intensity on the ergometer. Zinman [39]
reported that in diabetic subjects, an acute glucose-
lowering effect occurred with each exercise session. Gale
group [20] reported that immediately after low-intensity
exercise the incremental glucose was reduced by 16%.
They also observed that after the high-intensity exercise,
the incremental glucose area reduced by 14% immediately
after exercise and 35% 24 hours after exercise.
Most drugs that are otherwise suitable for transdermal
delivery do not achieve sufficiently high blood levels for
pharmacological activity when administered transdermally,
hence, it is sometimes necessary to enhance this delivery.
This can be achieved by chemical means namely by the use
of absorption promoters such as dimethylsulfoxide, Azone
(Trade Mark), and surfactants [40,41].
The limitations of this study were lack of true random-
ization and the inability to ascertain if the quantity of
84 A.T. Onigbinde et al.Glucosamine administered in this study was adequate
enough to affect the plasma glucose concentration. This
study concluded that glucosamine sulphate did not have
significant effect on plasma glucose of participants with
knee osteoarthritis.Acknowledgement
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